Ethical use of antiretroviral resources for HIV prevention in resource poor settings

Developing World Bioethics

Volumn 13, Issue 2, 2013, Pages 79-86

  Rennie, Stuart ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Developing world; HIV AIDS; Prevention; Rationing; Resource allocation; Treatment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ANTIRETROVIRAL THERAPY; ARTICLE; COITUS; DEVELOPING COUNTRY; DEVELOPING WORLD; DISEASE TRANSMISSION; ETHICS; FEMALE; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HIV/AIDS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METHODOLOGY; PREVENTION; PRIMARY PREVENTION; RATIONING; RESOURCE ALLOCATION; SERODIAGNOSIS; TREATMENT; TREATMENT OUTCOME; UTILIZATION REVIEW; VERTICAL TRANSMISSION;

ANTIRETROVIRAL THERAPY; DEVELOPING WORLD; HIV/AIDS; PREVENTION; RATIONING; RESOURCE ALLOCATION; TREATMENT;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; COITUS; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEALTH CARE RATIONING; HEALTH PRIORITIES; HEALTH RESOURCES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PRIMARY PREVENTION; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84880701418     PISSN: 14718731     EISSN: 14718847     Source Type: Journal    
DOI: 10.1111/dewb.12022     Document Type: Article

References (38)

1. H.S. Faust & P.T. Menzel, eds. 2012. Prevention vs. Treatment: what's the right balance? Oxford: Oxford University Press.
2. H.S. Faust & P.T. Menzel, eds. 2012. Introduction. In: Prevention vs. Treatment: what's the right balance? Oxford: Oxford University Press.
3. G. Miller etal. 2012. What is currently spent on prevention as compared to treatment? In Prevention vs. Treatment: what's the right balance? H.S. Faust, P.T. Menzel, eds. 2012. Oxford: Oxford University Press: 37-55.
4. M. Over. 2008. Prevention failure: the ballooning entitlement failure of US Global AIDS treatment funding and what to do about it. Center for Global Development, Working Paper #144. Available at: http://www.cgdev.org/content/publications/detail/15973/. [Accessed 25 Jan 2013].
5. World Health Organization. Global HIV/AIDS Response. Epidemic Update and Health Sector Progress Towards Universal Access. Progress Report. (2011) Available at: http://apps.who.int/iris/bitstream/10665/44787/1/9789241502986_eng.pdf. [Accessed 25 Jan 2013].
6. M. Posse etal. Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health 2008; 13(7): 904-913.
7. B. Waning, E. Diedrichsen & S. Moon. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc 2010; 13: 35.
8. F. Orsi, C. d'almeida. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries. Curr Opin HIV AIDS 2010; 5(3): 237-241.
9. A. Kagee etal. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Global Public Health 2011; 6(1): 83-97.
10. J.M. Baeten etal. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. NEJM 2012; July 12, 2012. Epub ahead of print.
11. R.M. Grant etal. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. NEJM 2010; 363: 2587-2599.
12. US Food and Drug Administration. 2012. Press Release. FDA approves first drug for reducing risk of sexually acquired HIV infection. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. [Accessed 25 Jan 2013].
13. M.S. Cohen etal. Prevention of HIV-1 infection with early antiretroviral therapy. NEJM 2011; 365: 493-505.
14. World Health Organization. Programmatic update. Antiretroviral treatment as prevention (TasP) for HIV and TB. 2012: 5. Available at: http://www.who.int/hiv/pub/mtct/programmatic_update_tasp/en/index.html. [Accessed 25 Jan 2013].
15. World Health Organization. Programmatic update. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in children (2012). Available at: http://www.who.int/hiv/PMTCT_update.pdf. [Accessed 25 Jan 2013].
16. R. Macklin & E. Cowan Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention. Health Affairs 2012; 31: 1537-1544.
17. R. Hecht etal. Critical choices in financing the response to the global HIV/AIDS pandemic. Health Affairs 2009; 28: 1591-1605.
18. D.W. Brock & D. Wikler Ethical challenges in long-term funding for HIV/AIDS. Health Affairs 2009; 28: 1666-1676.
19. B. Williams. 1973. A Critique of Utilitarianism. In Utilitarianism: For and Against. J.J.C. Smart & B. Williams. Cambridge: Cambridge University Press: 77-150.
20. L. Van Damme etal. Preexposure prophylaxis for HIV infection among African women. NEJM 2012; July 11, 2012. Epub ahead of print.
21. Microbicide Trials Network. 2011. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Available at: http://www.mtnstopshiv.org/node/3909. [Accessed 25 Jan 2013].
22. A. Van der Straten etal. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26: F13-F19.
23. D.P. Wilson. HIV Treatment as Prevention: Natural Experiments Highlight Limits of Antiretroviral Treatment as HIV Prevention. PLoS Med 2012; 9: e10001231.
24. J. Birungi etal. 2012. Lack of effectiveness of antiretroviral therapy (ART) as an HIV prevention tool for serodiscordant couples in a rural ART program without viral load testing in Uganda. Washington, D.C., Nineteenth International AIDS Conference. Abstract TUAC0103.
25. M.S. Cohen etal. HIV Treatment as Prevention: Debate and Commentary - Will Early Infection Compromise Treatment as Prevention Strategies? PLoS Med 2012; 9: e10011232.
26. M.S. Cohen etal. Antiviral agents and HIV prevention: controversies, conflict and consensus. AIDS 2012. Epub ahead of print.
27. M.M. Cassell etal. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006; 332: 605-607.
28. B.G. Williams etal. Pre-exposure prophylaxis (PrEP) versus treatment-as-prevention (TasP) for the control of HIV: Where does the balance lie? arXiv:1209.0364 [q-bio.PE]. Available at: http://arxiv.org/abs/1209.0364. [Accessed 25 Jan 2013].
29. L.O. Gostin & S.C. Kim. Ethical allocation of pre-exposure HIV prophylaxis. JAMA 2011; 305: 191-192.
30. UNAIDS. 2012. UNAIDS Report on the Global AIDS Epidemic. Available at: http://www.unaids.org/globalreport/Global_report.htm. [Accessed 25 Jan 2013].
31. L.A. Paxton, T. Hope & H.W. Jaffe. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 2007; 390: 89-93.
32. S. Rosen etal. Rationing antiretroviral treatment for HIV/AIDS in Africa: choices and consequences. PLoS Med 2005; 2: e303.
33. R. Macklin. 2004. Equity and ethics in access to HIV treatment - 3 by 5 initiative. Geneva: UNAIDS/WHO. Available at: http://www.who.int/ethics/en/background-macklin.pdf. [Accessed 25 Jan 2013].
34. N. Daniels. 2004. How to achieve fair distribution of ARTs in 3 by 5: fair process and legitimacy in patient selection. Geneva: UNAIDS/WHO. Available at: http://www.who.int/ethics/en/background-daniels.pdf. [Accessed 25 Jan 2013].
35. N. Daniels. 2007. Just Health: Meeting Health Needs Fairly. Oxford: Oxford University Press.
36. R. Ashcroft. Fair process and the redundancy of bioethics: a polemic. Public Health Ethics 2008; 1: 3-9.
37. S. Bennett & C. Chanfreau. Approaches to rationing antiretroviral treatment: ethical and equity implications. Bull World Health Org 2005; 83: 541-547.
38. V.K. Nyugen etal. Remedicalizing an epidemic: from treatment as prevention to treatment is prevention. AIDS 2011; 25: 291-293.